Table 2. HCRU and AA-related Medication Use During the Study Follow-up Period.
| Patients With Non-AT/AU | Patients With AT/AU | |||||
|---|---|---|---|---|---|---|
| Outcome | Non-AT/AU (n=1105) | Matched Controls Without AA (n=3315) | P Value | AT/AU (n=130) | Matched Controls Without AA (n=390) | P Value |
| HCRU visits, mean ± SD | ||||||
| Outpatient visits | 11.6±11.6 | 8.0±12.8 | <.001 | 14.5±11.8 | 7.1±9.6 | <.001 |
| Dermatologist visits | 3.4±5.1 | 0.4±1.7 | <.001 | 3.6±4.3 | 0.3±1.0 | <.001 |
| Psychiatrist visits | 0.3±2.3 | 0.3±1.6 | .559 | 0.1±0.7 | 0.3±1.3 | .272 |
| Psychologist visits | 0.3±1.8 | 0.4±3.7 | .278 | 0.2±1.6 | 0.1±0.7 | .199 |
| Any dermatologist visit, n (%) | 903 (81.7) | 548 (16.5) | <.001 | 93 (71.5) | 56 (14.4) | <.001 |
| Any psychiatrist visit, n (%) | 55 (5.0) | 195 (5.9) | .293 | 7 (5.4) | 22 (5.6) | 1.000 |
| Any psychologist visit, n (%) | 45 (4.1) | 140 (4.2) | .896 | 6 (4.6) | 14 (3.6) | .792 |
| Medication use, n (%) | ||||||
| Corticosteroids | ||||||
| Topical | 402 (36.4) | 51 (1.5) | <.001 | 38 (29.2) | 1 (0.3) | <.001 |
| Injectable | 568 (51.4) | 30 (0.9) | <.001 | 38 (29.2) | 6 (1.5) | <.001 |
| Oral | 121 (11.0) | 234 (7.1) | <.001 | 37 (28.5) | 20 (5.1) | <.001 |
| Methotrexate | 14 (1.3) | 1 (0.1) | <.001 | 11 (8.5) | 1 (0.3) | <.001 |
| Mental health | ||||||
| Antidepressants | 82 (7.4) | 312 (9.4) | .051 | 16 (12.3) | 27 (6.9) | .081 |
| Anxiolytics | 48 (4.3) | 129 (3.9) | .565 | 5 (3.8) | 12 (3.1) | .887 |
Abbreviations: AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis; HCRU, healthcare resource utilization.
HCRU visits are summarized per patient per year.